ArticleDiscover oncology2026
Identifying diagnostic markers and constructing a prognostic model for pancreatic cancer based on microarray and bioinformatic analysis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPancreatic cancer (PC) is one of the leading causes of cancer-related death worldwide. The lack of effective diagnostic biomarkers and therapeutic targets makes PC difficult to screen and treat. The aim of this study was to develop a diagnostic and survival-related gene signature for PC to construct a prognostic model.
methodsAn Arraystar RNA microarray was used to identify differentially expressed genes (DEGs) in clinical plasma samples between the PC group and the control group. We performed weighted gene co-expression network analysis (WGCNA) to identify significant modules of DEGs in the Gene Expression Omnibus (GEO) cohort and to obtain potential diagnostic hub genes by intersecting the significant module genes with microarray-derived DEGs. In addition, least absolute shrinkage and selection operator (LASSO) cox regression analysis were performed to construct a prognostic model. Moreover, clinical samples were analyzed to evaluate the expression levels of the independent risk genes.
resultsOur microarray data revealed 228 significantly upregulated mRNA in plasma samples. FERMT1, S100A14, KCNN4, PKM, and ITGA3 were identified as robust diagnostic biomarkers. Integrating these hub genes, we constructed a prognostic model, with the nomogram exhibiting prognostic value in TCGA cohort. Univariate and multivariate Cox proportional hazard analyses revealed that the expression of FERMT1, S100A14, and ITGA3 was an independent risk factor for poor prognosis. RT-qPCR validation in clinical plasma sample demonstrated concordant expression patterns of the independent risk gene, further supporting its potential prognostic relevance.
conclusionOur results revealed the potential biomarkers for the prediction of PC prognosis in addition to clinicopathological factors. Moreover, this study identifies potential biomarkers warranting further functional investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.